Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited
Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymp...
Gespeichert in:
| Veröffentlicht in: | Journal of the Turkish Academy of Dermatology 2020-09, Vol.14 (3), p.93-94 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 3 |
| container_start_page | 93 |
| container_title | Journal of the Turkish Academy of Dermatology |
| container_volume | 14 |
| creator | Okan, Gokhan Pilanci, Kezban Nur Demirkesen, Cuyan |
| description | Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymphocyte-associated antigen-4 and PD-1 antibodies. [...]if moderate or severe psoriatic lesions develop during nivolumab therapy, SSZ therapy cannot only treat the skin lesions but may also increase nivolumab’s anti-tumor effect. Authorship Contributions Surgical and Medical Practices: G.O., K.N.P., C.D., Concept: G.O., K.N.P., C.D., Design: G.O., K.N.P., C.D., Data Collection or Processing: G.O., K.N.P., C.D., Analysis or Interpretation: G.O., K.N.P., C.D., Literature Search: G.O., K.N.P., C.D., Writing: G.O., K.N.P., C.D. Conflict of Interest: No conflict of interest was declared by the authors. |
| doi_str_mv | 10.4274/jtad.galenos.2020.13007 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2506856958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A658915219</galeid><sourcerecordid>A658915219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1927-63b7a3affed5688435a1b49fdf4ac14826b00b6059b0d23e1d9136d835de6e1d3</originalsourceid><addsrcrecordid>eNptkW1LHDEQxxdpQVE_QwN9fds8bLIb3x3aVsHTUq7Qd2F2k1xz7CZnkhPu2zerggoygZnM_GcG5ldVXwiuG9o237YZdL2B0fiQaooprgnDuD2qTopvF0w2fz-9iY-r85S2GGMqKW8ZP6kO62ggT8ZnFCz6lUJ0kFxCS5tNRDfeZQfZBT9X79xjGPcT9Gj9z0TYHZANEa1MhpSLaEArGN3GQ5m1MiP4MMEFWvryBjcvuIr7DfptHl1y2eiz6rOFMZnzF39a_fnxfX15vbi9_3lzubxdDETSdiFY3wIDa43mousaxoH0jbTaNjCQpqOix7gXmMsea8oM0ZIwoTvGtRHlx06rr89zdzE87E3Kahv20ZeVinIsOi4k715V8zGV8zbkCMPk0qCWgneScEpkUdUfqIppM7kheGNdyb9raJ8bhhhSisaqXXQTxIMiWM0E1UxQvRBUM0H1RJD9Bz6Tkig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506856958</pqid></control><display><type>article</type><title>Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Okan, Gokhan ; Pilanci, Kezban Nur ; Demirkesen, Cuyan</creator><creatorcontrib>Okan, Gokhan ; Pilanci, Kezban Nur ; Demirkesen, Cuyan</creatorcontrib><description>Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymphocyte-associated antigen-4 and PD-1 antibodies. [...]if moderate or severe psoriatic lesions develop during nivolumab therapy, SSZ therapy cannot only treat the skin lesions but may also increase nivolumab’s anti-tumor effect. Authorship Contributions Surgical and Medical Practices: G.O., K.N.P., C.D., Concept: G.O., K.N.P., C.D., Design: G.O., K.N.P., C.D., Data Collection or Processing: G.O., K.N.P., C.D., Analysis or Interpretation: G.O., K.N.P., C.D., Literature Search: G.O., K.N.P., C.D., Writing: G.O., K.N.P., C.D. Conflict of Interest: No conflict of interest was declared by the authors.</description><identifier>ISSN: 1307-394X</identifier><identifier>EISSN: 1307-394X</identifier><identifier>DOI: 10.4274/jtad.galenos.2020.13007</identifier><language>eng</language><publisher>Istanbul: Galenos Yayinevi Tic. Ltd</publisher><subject>Arthritis ; Conflicts of interest ; Dermatologic agents ; Dermatology ; Drug therapy ; Formulae, receipts, prescriptions ; Inflammatory bowel disease ; Ipilimumab ; Melanoma ; Metastasis ; Neutrophils ; Psoriasis ; Skin ; Skin cancer ; Tumor necrosis factor-TNF</subject><ispartof>Journal of the Turkish Academy of Dermatology, 2020-09, Vol.14 (3), p.93-94</ispartof><rights>COPYRIGHT 2020 Galenos Yayinevi Tic. Ltd.</rights><rights>2020. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-0901-819X ; 0000-0003-1457-1886 ; 0000-0002-3045-9942</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Okan, Gokhan</creatorcontrib><creatorcontrib>Pilanci, Kezban Nur</creatorcontrib><creatorcontrib>Demirkesen, Cuyan</creatorcontrib><title>Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited</title><title>Journal of the Turkish Academy of Dermatology</title><description>Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymphocyte-associated antigen-4 and PD-1 antibodies. [...]if moderate or severe psoriatic lesions develop during nivolumab therapy, SSZ therapy cannot only treat the skin lesions but may also increase nivolumab’s anti-tumor effect. Authorship Contributions Surgical and Medical Practices: G.O., K.N.P., C.D., Concept: G.O., K.N.P., C.D., Design: G.O., K.N.P., C.D., Data Collection or Processing: G.O., K.N.P., C.D., Analysis or Interpretation: G.O., K.N.P., C.D., Literature Search: G.O., K.N.P., C.D., Writing: G.O., K.N.P., C.D. Conflict of Interest: No conflict of interest was declared by the authors.</description><subject>Arthritis</subject><subject>Conflicts of interest</subject><subject>Dermatologic agents</subject><subject>Dermatology</subject><subject>Drug therapy</subject><subject>Formulae, receipts, prescriptions</subject><subject>Inflammatory bowel disease</subject><subject>Ipilimumab</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Neutrophils</subject><subject>Psoriasis</subject><subject>Skin</subject><subject>Skin cancer</subject><subject>Tumor necrosis factor-TNF</subject><issn>1307-394X</issn><issn>1307-394X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkW1LHDEQxxdpQVE_QwN9fds8bLIb3x3aVsHTUq7Qd2F2k1xz7CZnkhPu2zerggoygZnM_GcG5ldVXwiuG9o237YZdL2B0fiQaooprgnDuD2qTopvF0w2fz-9iY-r85S2GGMqKW8ZP6kO62ggT8ZnFCz6lUJ0kFxCS5tNRDfeZQfZBT9X79xjGPcT9Gj9z0TYHZANEa1MhpSLaEArGN3GQ5m1MiP4MMEFWvryBjcvuIr7DfptHl1y2eiz6rOFMZnzF39a_fnxfX15vbi9_3lzubxdDETSdiFY3wIDa43mousaxoH0jbTaNjCQpqOix7gXmMsea8oM0ZIwoTvGtRHlx06rr89zdzE87E3Kahv20ZeVinIsOi4k715V8zGV8zbkCMPk0qCWgneScEpkUdUfqIppM7kheGNdyb9raJ8bhhhSisaqXXQTxIMiWM0E1UxQvRBUM0H1RJD9Bz6Tkig</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Okan, Gokhan</creator><creator>Pilanci, Kezban Nur</creator><creator>Demirkesen, Cuyan</creator><general>Galenos Yayinevi Tic. Ltd</general><general>Galenos Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-0901-819X</orcidid><orcidid>https://orcid.org/0000-0003-1457-1886</orcidid><orcidid>https://orcid.org/0000-0002-3045-9942</orcidid></search><sort><creationdate>20200901</creationdate><title>Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited</title><author>Okan, Gokhan ; Pilanci, Kezban Nur ; Demirkesen, Cuyan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1927-63b7a3affed5688435a1b49fdf4ac14826b00b6059b0d23e1d9136d835de6e1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Arthritis</topic><topic>Conflicts of interest</topic><topic>Dermatologic agents</topic><topic>Dermatology</topic><topic>Drug therapy</topic><topic>Formulae, receipts, prescriptions</topic><topic>Inflammatory bowel disease</topic><topic>Ipilimumab</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Neutrophils</topic><topic>Psoriasis</topic><topic>Skin</topic><topic>Skin cancer</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Okan, Gokhan</creatorcontrib><creatorcontrib>Pilanci, Kezban Nur</creatorcontrib><creatorcontrib>Demirkesen, Cuyan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of the Turkish Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Okan, Gokhan</au><au>Pilanci, Kezban Nur</au><au>Demirkesen, Cuyan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited</atitle><jtitle>Journal of the Turkish Academy of Dermatology</jtitle><date>2020-09-01</date><risdate>2020</risdate><volume>14</volume><issue>3</issue><spage>93</spage><epage>94</epage><pages>93-94</pages><issn>1307-394X</issn><eissn>1307-394X</eissn><abstract>Dear Editor, Checkpoint inhibition can cause various immune-related adverse events in any organ but skin toxicity occurs most frequently [1]. In the genetically susceptible animal model, not only did blocking TNF-α reduce colitis but it also increased the anti-tumor activity of anti-cytotoxic T lymphocyte-associated antigen-4 and PD-1 antibodies. [...]if moderate or severe psoriatic lesions develop during nivolumab therapy, SSZ therapy cannot only treat the skin lesions but may also increase nivolumab’s anti-tumor effect. Authorship Contributions Surgical and Medical Practices: G.O., K.N.P., C.D., Concept: G.O., K.N.P., C.D., Design: G.O., K.N.P., C.D., Data Collection or Processing: G.O., K.N.P., C.D., Analysis or Interpretation: G.O., K.N.P., C.D., Literature Search: G.O., K.N.P., C.D., Writing: G.O., K.N.P., C.D. Conflict of Interest: No conflict of interest was declared by the authors.</abstract><cop>Istanbul</cop><pub>Galenos Yayinevi Tic. Ltd</pub><doi>10.4274/jtad.galenos.2020.13007</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-0901-819X</orcidid><orcidid>https://orcid.org/0000-0003-1457-1886</orcidid><orcidid>https://orcid.org/0000-0002-3045-9942</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1307-394X |
| ispartof | Journal of the Turkish Academy of Dermatology, 2020-09, Vol.14 (3), p.93-94 |
| issn | 1307-394X 1307-394X |
| language | eng |
| recordid | cdi_proquest_journals_2506856958 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Arthritis Conflicts of interest Dermatologic agents Dermatology Drug therapy Formulae, receipts, prescriptions Inflammatory bowel disease Ipilimumab Melanoma Metastasis Neutrophils Psoriasis Skin Skin cancer Tumor necrosis factor-TNF |
| title | Treatment of Psoriasis After Initiation of Nivolumab Therapy for Metastatic Malignant Melanoma: An Ancient Drug Revisited |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A10%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Psoriasis%20After%20Initiation%20of%20Nivolumab%20Therapy%20for%20Metastatic%20Malignant%20Melanoma:%20An%20Ancient%20Drug%20Revisited&rft.jtitle=Journal%20of%20the%20Turkish%20Academy%20of%20Dermatology&rft.au=Okan,%20Gokhan&rft.date=2020-09-01&rft.volume=14&rft.issue=3&rft.spage=93&rft.epage=94&rft.pages=93-94&rft.issn=1307-394X&rft.eissn=1307-394X&rft_id=info:doi/10.4274/jtad.galenos.2020.13007&rft_dat=%3Cgale_proqu%3EA658915219%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506856958&rft_id=info:pmid/&rft_galeid=A658915219&rfr_iscdi=true |